List of RNA Therapies Companies in Canada - 4

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

enGene Inc. has developed a highly flexible nucleotide (DNA and RNAi) delivery technology that targetsmucosal tissues and can be used to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others.

Providence Therapeutics Holdings Inc is a clinical-stage biotechnology company focused on drug development and platform development. The Providence mRNA Medicines platform is comprised of four integrated platforms: 1) mRNA Medicines Platform, 2) NextGen lipid nanoparticles (LNP), 3) Manufacturing Platform and 4) Regulatory Platform. Providence’s mRNA and NextGen LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application optimized LNP. The Providence proprietary NextGen LNP, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery. Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting. For more information, please visit providencetherapeutics.com